Xconomy

MAY 17, 2019

A lawsuit is now claiming that many top generic drug makers routinely conspired to avoid competition. During his tenure as FDA commissioner, Scott Gottlieb often spoke about generics as a market force that could help tame climbing drug prices. But such tools only work when companies play fair.

Pricing 79

Pricing Competition Tool Marketing 79

Xconomy

DECEMBER 14, 2018

to offer competitive pricing pressure. But the university also allowed them to patent the improvements they made, which enabled them to slap higher prices on each new version. In the nearly 100 years since insulin’s discovery, no generic version has become available in the U.S. FDA commissioner Scott Gottlieb is trying to change that.

Patents 77

Patents Pricing Competition San Diego 77

Xconomy

AUGUST 16, 2016

An obvious place to look for help is the venture community—Bruce Booth of Atlas Ventures pointed out in a recent blog that venture capital is doing well, and is positioned to do even better in the future. It is the hope of new blockbuster drugs that keeps government regulators at bay.

Product 40

Product Journal Venture Capital Demand 40

Xconomy

MAY 10, 2018

Eli Lilly is making a splash in the fast-moving, highly competitive field of cancer immunotherapy. billion cash deal to acquire Armo BioSciences, the Indianapolis company has placed one of the boldest bets yet that cytokine drugs could be critical in expanding immunotherapy’s reach.

Competition 49

Competition Pricing San Diego Company 49

Xconomy

AUGUST 11, 2017

The FDA reported that generic drug approvals are set to hit a record ; the agency under Commissioner Scott Gottlieb has moved this summer to increase generic competition and lower the nation’s high drug prices. Meanwhile, drug-price hawks can sharpen their talons on a report this week from The New York Times and ProPublica.

Pricing 52

Pricing News Report Competition 52

Xconomy

OCTOBER 9, 2017

Steve Case, venture capitalist, author, and co-founder of AOL, is preparing to hit the road this week on his sixth Rise of the Rest tour, where he travels to emerging innovation hubs in search of investment-worthy tech startups and to highlight the growth happening outside of places like Silicon Valley and Boston.

Media 71

Media Invest Startup Venture Capital 71

Xconomy

OCTOBER 18, 2016

But the drugs aren’t cures, and competition looms. They are on more solid footing than they were, but there’s no such thing as solid footing in this industry,” says Rajeev Shah, a managing director at biotech investment firm RA Capital, which had been a Vertex investor but no longer is. Has Vertex has learned from its past missteps?

Startup 40

Startup Research Sales Organization 40

Xconomy

AUGUST 26, 2016

Critics say Mylan has been emboldened by the recall of EpiPen’s only competition last fall. Its latest hike has brought the two-pack of injectors to more than $600, according to the Wall Street Journal. In response, Mylan has offered more discounts and rebates , but it has not lowered the list price.

Pricing 40

Pricing Thousand Oaks Startup Research 40

Xconomy

JULY 20, 2018

You’ve made it to Friday. Time to curl up in your cubicle, pop open one of these in-depth, entertaining reads, and catch up on some of what you missed during a busy week. This week we’re taking a look at all the political stories that are coming out of the tech world.

Entertainment 49

Entertainment Venture Capital Buzzfeed Journal 49

Xconomy

SEPTEMBER 29, 2016

Each company is investing untold billions of dollars in developing AI technologies, betting on a future defined by computer systems that can perceive, reason, advise, and decide. As the technology has advanced, so has the competitive landscape.

Artificial Inteligence 40

Artificial Inteligence Technical Review Technical Advisors Research 40